VSM Wealth Advisory LLC Purchases Shares of 2,697 Pfizer Inc. (NYSE:PFE)

VSM Wealth Advisory LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,697 shares of the biopharmaceutical company’s stock, valued at approximately $72,000.

A number of other large investors have also made changes to their positions in PFE. Compass Ion Advisors LLC increased its stake in Pfizer by 55.6% during the fourth quarter. Compass Ion Advisors LLC now owns 24,295 shares of the biopharmaceutical company’s stock valued at $645,000 after acquiring an additional 8,677 shares during the period. Enhancing Capital LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $1,104,000. Xponance Inc. increased its position in shares of Pfizer by 4.2% during the fourth quarter. Xponance Inc. now owns 851,248 shares of the biopharmaceutical company’s stock valued at $22,584,000 after purchasing an additional 34,344 shares during the period. Generali Asset Management SPA SGR acquired a new position in shares of Pfizer in the fourth quarter valued at $11,538,000. Finally, Horizon Investments LLC lifted its position in Pfizer by 1.6% in the fourth quarter. Horizon Investments LLC now owns 82,602 shares of the biopharmaceutical company’s stock worth $2,156,000 after purchasing an additional 1,271 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several analyst reports. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Finally, StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Down 0.5 %

Shares of NYSE PFE opened at $26.18 on Thursday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The firm’s 50-day simple moving average is $26.19 and its 200 day simple moving average is $27.08. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $148.35 billion, a price-to-earnings ratio of 18.57, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the business earned $0.10 earnings per share. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.